Ionis Pharmaceuticals, Inc.
IONS
$43.03
$0.050.12%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 452.05M | 131.61M | 226.58M | 133.81M | 225.25M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 452.05M | 131.61M | 226.58M | 133.81M | 225.25M |
| Cost of Revenue | 221.61M | 194.92M | 249.32M | 220.83M | 226.23M |
| Gross Profit | 230.44M | -63.31M | -22.74M | -87.02M | -978.00K |
| SG&A Expenses | 90.62M | 83.55M | 88.08M | 61.64M | 65.11M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 312.23M | 278.47M | 337.40M | 282.47M | 291.34M |
| Operating Income | 139.82M | -146.86M | -110.82M | -148.66M | -66.09M |
| Income Before Tax | 123.53M | -146.82M | -107.04M | -144.10M | -66.20M |
| Income Tax Expenses | -20.00K | 116.00K | -2.69M | -3.62M | 64.00K |
| Earnings from Continuing Operations | 123.55M | -146.94M | -104.35M | -140.48M | -66.27M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 123.55M | -146.94M | -104.35M | -140.48M | -66.27M |
| EBIT | 139.82M | -146.86M | -110.82M | -148.66M | -66.09M |
| EBITDA | 142.68M | -144.05M | -108.12M | -145.68M | -63.00M |
| EPS Basic | 0.78 | -0.93 | -0.66 | -0.95 | -0.45 |
| Normalized Basic EPS | 0.56 | -0.57 | -0.41 | -0.61 | -0.27 |
| EPS Diluted | 0.70 | -0.93 | -0.66 | -0.95 | -0.45 |
| Normalized Diluted EPS | 0.49 | -0.57 | -0.41 | -0.61 | -0.27 |
| Average Basic Shares Outstanding | 159.14M | 158.74M | 158.00M | 148.59M | 145.96M |
| Average Diluted Shares Outstanding | 182.33M | 158.74M | 158.00M | 148.59M | 145.96M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |